Autopsy report · NCT05245916

IBI397 or Combination Therapies in Patients With Advanced Malignancies

“Due to the company's development strategy adjustment”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 1

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.

Sponsor type

Industry

Conditions

Advanced Malignancies

Interventions

IBI397; IBI397+Sintilimab; IBI397+Rituximab

Participants

0

Sites

1

Countries

China

Trials that died the same way

• A Study of IBI351 in Combination With Cetuximab in Subjects With KRAS G12C Mutated Metastatic Colorectal Cancer
  “company development strategy adjustment” (84% match in meaning)
• Mesenchymal Stem Cells in the Treatment of Refractory Primary Immune Thrombocytopenia
  “Due to corporate strategic adjustment.” (82% match in meaning)
• Safety and Effectiveness of ABM-168 in Adults with Advanced Solid Tumors.
  “Due to development strategy change.” (82% match in meaning)
• Study of SIM0501 Alone and in Combination in Patients With Advanced Solid Tumors
  “Company development strategy change” (78% match in meaning)
• Study of NIB101 in Participants With Advanced Solid Tumors
  “due to the reconsideration of development strategy” (75% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.